Abstract
The journey from myopia being an intriguing scientific puzzle to part of clinical practice has been a long and varied path. Chew Sek Jin was one of the pioneers on this journey and, as director of the Singapore Eye Research Institute, initiated an ambitious research program that has helped us get to where we are today. His work was data-driven, embracing the power of epidemiological and longitudinal studies. He emphasized both the public health aspects and clinical management of myopia, pioneering the use of atropine in Singapore. With his work with Josh Wallman, he recognized the importance of research into the biological mechanisms of myopia.
| Original language | English |
|---|---|
| Pages (from-to) | 240-259 |
| Number of pages | 20 |
| Journal | Optometry and Vision Science |
| Volume | 102 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of '2024 Chew Sek Jin Memorial Lecture: “Are we there yet?”'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver